Abstract
Alterations in brain blood vessels in mice precede the neural dysfunction associated with Alzheimer's disease. The finding highlights potential targets for drug development. See Letter p.512 There are known connections between the Alzheimer's-disease-linked APOE4 gene and cerebrovascular integrity. However, the mechanisms that drive known blood–brain-barrier dysfunction both in rodent models and in APOE4-associated neurological disorders are unknown. Here, Berislav Zlokovic and colleagues report that APOE4 activates a matrix metalloproteinase pathway in cells forming the blood–brain barrier in mice, leading to its breakdown and the neuronal uptake of blood-derived neurotoxic proteins. In turn, microvascular and cerebral blood flow are reduced; together, these deficits can initiate neurodegenerative changes in rodents. The authors suggest that cyclophilin A (CypA), a component of the APOE4-activated pathway, is a potential target for treating APOE4-mediated neuronal dysfunction. Treatment with the CypA inhibitor cyclosporine A restores the blood–brain barrier in APOE4 mice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
